Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $64.68 Analyst target: $91.08 Upside: 40.82%
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. The company is well-positioned to meet significant unmet medical needs in oncology, emphasizing the potential to improve patient outcomes and transform treatment approaches. With a robust proprietary technology platform and a commitment to advancing clinical trials and securing regulatory approvals, CG Oncology represents a compelling investment opportunity for institutional investors interested in pioneering advancements in cancer care.
See the full interactive analysis & chart →Informational only — not investment advice.